TOVX - Latest News
Theriva Biologics, Inc. (TOVX), operates in Healthcare / Biotechnology, trades on AMEX.
Market capitalization stands near $11.2M. Beta to the broader market is 1.18.
The article list below shows the most recent TOVX headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent TOVX Headlines
Theriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial Results
globenewswire.com - May 5, 2026
– Alignment with the FDA on the Phase 3 trial design of VCN-01 (zabilugene almadenorepvec) for treatment of metastatic pancreatic ductal adenocarcinom
Theriva™ Biologics anuncia la próxima presentación de datos adicionales del ensayo clínico VIRAGE de Fase 2b del VCN-01 para el cáncer de páncreas metastásico en la Reunión Anual de la AACR de 2026
globenewswire.com - Apr 18, 2026
- Los análisis de la respuesta tumoral, los biomarcadores y los subgrupos del ensayo clínico VIRAGE de Fase 2b respaldan el mecanismo de acción inmuno
Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting
globenewswire.com - Apr 17, 2026
- Tumor reponse, biomarker, and subgroup analyses from the VIRAGE Phase 2b clinical trial support a VCN-01 immune-mediated mode of action and demonstr
Theriva™ Biologics Announces Positive End-of-Phase 2 Meeting with U.S. FDA Regarding the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma
globenewswire.com - Mar 23, 2026
- Successful meeting with FDA enables advancement into proposed Phase 3 clinical trial of VCN-01 in combination with gemcitabine/nab-paclitaxel for th
Theriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros del ejercicio 2025
globenewswire.com - Mar 13, 2026
- Avances en el desarrollo clínico del VCN-01 para el adenocarcinoma ductal pancreático y el retinoblastoma - - Concesión de la licencia de SYN-020 a
How News Affects TOVX Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track TOVX's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked TOVX news questions
- What is the latest TOVX news headline?
- The most recent TOVX headline (May 5, 2026) is "Theriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial Results". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the TOVX news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What TOVX news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual TOVX options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.